Interestingly, both LILRB4/CD85k and CD33 are therapeutic targets in AML [57–63] and have shown potential as therapeutic vulnerabilities in KMT2A-rearranged ALL. Here, LILRB4 is linked to acute lymphoblastic leukemia.